Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli

Human Vaccines

Volumn 2, Issue 1, 2006, Pages 14-23

  Zhou, Zhiyong ^a,b   Todd, Charles W ^a,b   Wohlhueter, Robert M ^a   Price, April ^a   Xiao, Lihua ^a   Schnake, Paul ^a   Bonner, Phillip Cullison ^a   Martin, Amy M ^a   Goldman, Ira F ^a   De La Vega, Patricia ^c   Udhayakumar, Venkatachalam ^a   Lal, Altaf A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Atlanta Research and Education Foundation Inc   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Characterization; FALVAC 1A; Immunogenicity; Malaria synthetic antigen; Purification

Indexed keywords

ALUMINUM PHOSPHATE; ANTIGEN; EPITOPE; PROTEIN FALVAC 1A; QS 21; SORBITAN OLEATE; SQUALENE; UNCLASSIFIED DRUG; VACCINE;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; DRUG INHIBITION; ESCHERICHIA COLI; GENE CONSTRUCT; GENE EXPRESSION; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; MALARIA; NONHUMAN; PARASITE; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SPOROZOITE;

EID: 33646369694     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2.1.2437     Document Type: Article

References (37)

1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: Past, present, and future. Lancet Infect Dis 2004; 4:327-36.
2. Breman J, Egan A, Keusch G. The intolerable burden of malaria: A new look at the numbers. Am J Trop Med Hyg 2001; 64:iv-vii.
3. Malaria, Disease burden and epidemiological trends. World health Organization 2002, (Available at http://www.who.int/tdr/diseases/malaria/files/ direction.pdf).
4. Long CA, Hoffman SL. Parasitology. Malaria-From infants to genomics to vaccines. Science 2002; 297:345-7.
5. Moree M, Ewart S, Diggs C. Strength in unity. Nature 2004; 430:938-9.
6. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovatt C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois M-C, Demoitié M-A, Dubovsky F, Menéndez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS, S/AS02 vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. The Lancet 2004; 364:1411-20.
7. Nosten F, Luxemburger C, Kyle DE, Gordon DM, Ballou WR, Sadoff JC, Brockman A, Permpanich B, Chongsuphajaisiddhi T, Heppner DG. Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia. Am J Trop Med Hyg, 1997; 56:526-32.
8. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664-73.
9. World Health Organization Initiative for Vaccine Research document: Table of all malaria vaccine development. (Available at: http://www.who.int/ vaccine_research/documents/en/).
10. Shi YP, Hasnain SE, Sacci JB, Holloway BP, Fujioka H, Kumar N, Wohlhueter RM, Hoffman SL, Collins WE, Lal AA. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc Nat Acad Sci 1999; 96:1615-20.
11. Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, Schneider J, Hannan C, Roy M, Gilbert SC, Peto TE, Hill AV. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in nonimmune volunteers. Vaccine 2003; 21:1995-2002.
12. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine 2003; 9:729-35.
13. Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975; 24:397-401.
14. Hoffman SL. Save the children. Nature 2004; 430:940-0.
15. Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania J-G, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 2004; 172:5561-9.
16. SShi YP, Das P, Holloway B, Udhayakumar V, Tongren JE, Candal F, Biswas S, Ahmad R, Hasnain SE, Lal AA. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 2000; 18:2902-14.
17. Rafi-Janajreh A, Tongren JE, Kensil C, Hackett C, Candal F, Lal A, Udhayakumar V. Influence of adjuvants in inducing immune responses to different epitopes induced in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice. Exp Parasitol 2002; 101:3-12.
18. Kurland C, Gallant J. Errors of heterologous protein expression. Curr Opin Biotechnol 1996; 7:489-93.
19. Zhou Z, Schnake P, Xiao L, Lal AA. Enhanced expression of a recombinant malaria candidate vaccine in Escherichia coli by codon optimization. Protein Expression Purification 2004; 34:87-94.
20. Sreerama N, Woody RW. Estimation of protein secondary structure from CD spectra: Comparison of CONTIN, SELCON and CDSSTR methods with an expanded reference set. Anal Biochem 2000; 287:252-60.
21. Shi YP, Udhayakumar V, Oloo AJ, Nahlen BL, Lal AA. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg 1999; 60:135-41.
22. Ockenhouse CF, Barbosa A, Blackall DP, Murphy CI, Kashala O, Dutta S, Lanar DE, Daugherty J. Sialic acid-dependent binding of baculovirus-expressed recombinant antigens from Plasmodium falciparum EBA-175 to Glycophorin A. Molecular Biochem Parasitol 2001; 113:9-21.
23. Harnyuttanakorn P, McBride JS, Donachie S, Heidrich H, Ridley RG. Inhibitory monoclonal antibodies recognise epitopes adjacent to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falciparum. Molec Biochem Parasitol 1992; 55:177-86.
24. Jakobsen PH, Heegaard PMH, Koch C, Wasniowska K, Lemnge MM, Jensen JB, Sim BKL. Identification of an erythrocyte binding peptide from the erythrocyte binding antigen, EBA-175, which blocks parasite multiplication and induces peptide-blocking antibodies. Infect Immunity 1998; 66:4203-7.
25. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, Sette A. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 2002; 168:5499-06.
26. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001; 19:4652-60.
27. Porath J. Immobilized metal ion affinity chromatography. Protein Expression Purification 1992; 3:263-81.
28. Hirel PH, Schmitter MJ, Dessen P, Fayat G, Blanquet S. Extent of N-terminal methionine excision from Escherichia coli protein is governed by the side-chain length of the penultimate amino acid. Proc Natl Acad Sci USA 1989; 86:8247-51.
29. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
30. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000; 68:2617-20.
31. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, eds. Vaccine design, the subunit approach. New York: Plenum Press, 1995:141-228.
32. Lawrence G, Cheng Q, Reed C, Taylor D, Stowers A, Cloonan N, Rzepczyk C, Smillie A, Anderson K, Pombo D, Allworth A, Eisen D, Anders R, Saul A. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in nonimmune volunteers. Vaccine 2000; 18:1925-31.
33. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003; 22:30-41.
34. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, Maier C, Andrews L, Andersen RF, Gilbert S, Poulton I, Webster D, Dubovsky F, Tierney E, Sarpotdar P, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Thornton GB, Hill AV. Safety, immunogenicity and efficacy of a preerythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 2005; 23:857-64.
35. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991; 146:431-7.
36. Kensil CR, Wu JY, Soltysik S. Structural and Immunological characterization of the vaccine adjuvant QS-21. In: Powell MF, Newman MJ, eds. Vaccine design, the subunit approach. New York: Plenum Press, 1995:525-41.
37. Stoute JA, Sloaui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M. A preliminary evaluation of a recombinant Circumsporozoite protein vaccine against Plasmodium falciparum malaria. New England J Med 1997; 336:86-91.